Edward Lee Carter: What Is Changing in Antiplatelet Deprescribing and Why It Matters
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:
“Antiplatelet Deprescribing: What’s Changing Why It Matters
Based on 2026 Anticoagulation Forum Clinical Guidance
The Big Shift:
Evidence increasingly shows that adding antiplatelets to anticoagulation substantially increases bleeding risk with uncertain antithrombotic benefit. Many patients on dual therapy don’t need to be. Time to rethink long-standing habits!
Do:
- Periodically review indication, bleeding risk, timing, dose of antiplatelet therapy
- Evaluate the need to restart APT only when clinically indicated in the absence of OAC
- Continue APT for patients with ASCVD on rivaroxaban 2.5 mg BID (stable CAD, stable and post-intervention PAD)
- Add PPI for gastroprotection if a patient must remain on concomitant therapy
- Evaluate indication for anticoagulation, particularly in VTE
Don’t:
- Routinely use APT for primary prevention
- Routinely add APT to OAC in stable ASCVD
- Routinely use APT with mechanical prosthetic heart valves
- Add APT for acute ischemic stroke in the setting of AF
- Wait until a patient bleeds before stopping inappropriate APT — be proactive!
Consider:
- Evaluating the need to add APT during periprocedural periods if anticoagulation is held
- Shared decision-making with patients using visual decision-aids for bleeding vs. thrombotic risk
Antiplatelet Deprescribing — Quick-Hit Scenario Guide
- Stable CAD with OAC (PCI, MI, or CABG more than 6–12 months prior): stop antiplatelet therapy.
- Stable PAD with OAC and no other indication for antiplatelet therapy: stop antiplatelet therapy.
- Prior TIA or stroke with newly diagnosed AF or VTE: stop antiplatelet therapy.
- Following PCI within the past 6–12 months: continue antithrombotic therapy, preferably with OAC plus a P2Y12 inhibitor; stop aspirin after 1–4 weeks.
- Patients with HeartMate III or BiVAD support: stop antiplatelet therapy.
- Patients with HeartMate II, HVAD, or total artificial heart support: continue antiplatelet therapy.
- LAAO patients receiving OAC for a non-AF indication: stop antiplatelet therapy.
- Mechanical heart valve patients treated with warfarin: stop antiplatelet therapy, except in selected On-X valve cases.
- APS patients with arterial thrombosis and additional cardiovascular risk factors: continue antiplatelet therapy.
Stewardship Action Items:
- Clarify ownership of APT decisions across inpatient, outpatient, procedural settings
- Implement EHR-based triggers to flag patients on combined antithrombotic therapy
- Standardize expectations for antiplatelet duration reassessment
- Develop patient-facing education tools to support deprescribing conversations
Bottom line:
If your patient is on therapeutic anticoagulation, ask yourself — do they really still need that antiplatelet? More often than not, the answer is no.
Source: Anticoagulation Forum – Antithrombotic Clinical Guidance (April 2026)”
Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health